A Phase II Study of Pazopanib (GW786034, NSC# 737754) in Children, Adolescents and Young Adults with Refractory Solid Tumors
A Phase II Study of Pazopanib (GW786034, NSC# 737754) inChildren, Adolescents and Young Adults with Refractory SolidTumors
A Phase II Study of Pazopanib (GW786034, NSC# 737754) in Children, Adolescents and Young Adults with Refractory Solid Tumors
100 Clinical Results associated with Novartis Pharma Services AG
0 Patents (Medical) associated with Novartis Pharma Services AG
100 Deals associated with Novartis Pharma Services AG
100 Translational Medicine associated with Novartis Pharma Services AG